Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GMNN | O75496 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643924 | 1.00 | SMPD1 (0.46) | SMPD1MAPK1MAPTMEN1GMNN | |
| SCHEMBL26927593 | 1.00 | SMPD1 (0.46) | SMPD1MAPK1MAPTMEN1GMNN | |
| SCHEMBL27889175 | 0.92 | FABP3 (0.50) | SLC6A5CES2 | |
| SCHEMBL5916140 | 0.92 | FABP3 (0.50) | SLC6A5CES2 | |
| SCHEMBL30673761 | 0.88 | MAPT (0.44) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL30673768 | 0.88 | MAPT (0.44) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL31173704 | 0.88 | MAPT (0.44) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL5190821 | 0.88 | MAPT (0.44) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL28001919 | 0.87 | MAPK1 (0.41) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL28001916 | 0.87 | MAPK1 (0.41) | MAPK1MAPTMEN1GMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | claimed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | claimed |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | CELANESE EVA PERFORMANCE POLYMERS LLC | 2026-04-09 | — | — | US | disclosed |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4312951-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | Celanese EVA Performance Polymers LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220313616-A1 | Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles | CELANESE EVA PERFORMANCE POLYMERS LLC | 2022-10-06 | — | — | US | disclosed |
| WO-2022212300-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | P4HTM, ITGAM, TIMM44 | SMPD1 2048/4885MAPK1 1634/4885MAPT 640/4885 |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | GHITM, O60361, P4HTM | SMPD1 1091/4885MAPK1 2896/4885MAPT 1202/4885 |
| US-20070264206-A1 | Mucosal formulation | MUC1, CHMP4B, VMA21 | SMPD1 145/4885MAPK1 1957/4885MAPT 1818/4885 |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | SAMM50, OPRM1, IRAK4 | SMPD1 1480/4885MAPK1 2728/4885MAPT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.